JPAD - Journal of Prevention of Alzheimer’s Disease, published by Springer Basel AG, is a premier academic journal dedicated to advancing research in the critical field of Alzheimer’s disease prevention. Its impactful contributions to the fields of neurology, psychiatry, and mental health have led it to achieve a Q1 ranking in multiple categories, including neurology (clinical) and psychiatry and mental health. Since its inception in 2017, JPAD has become an essential platform for researchers and professionals aiming to stay at the forefront of developments in Alzheimer’s disease research, prevention strategies, and innovative therapies. The journal provides a valuable open access option for disseminating high-quality research to a global audience, enhancing its visibility and impact. With its strategic focus and rigorous peer-review process, JPAD is committed to fostering collaboration and knowledge exchange among scientists, clinicians, and practitioners, ultimately contributing to the global effort to combat Alzheimer's disease.

NEUROREPORT is a distinguished journal in the field of neuroscience, published by Lippincott Williams & Wilkins. With an ISSN of 0959-4965 and an E-ISSN of 1473-558X, the journal has established itself as a vital platform for disseminating innovative research and developments in the dynamic area of neuroscience since its inception in 1990. Currently, it is positioned in the Q3 category of the 2023 Journal Rankings, reflecting its respectable standing within the community of neuroscience professionals, ranked #74 out of 113 in general neuroscience on Scopus, placing it in the 34th percentile. While it operates on a traditional subscription model, NEUROREPORT is committed to fostering knowledge sharing in the realm of neurobiology, neuropharmacology, and cognitive studies among researchers, professionals, and students alike. With its broad scope and commitment to scientific excellence, the journal continues to be a cornerstone for those seeking to stay ahead in the evolving landscape of neurological research.

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, published by WILEY, stands at the forefront of research in the fields of neurology and psychiatry. As an Open Access journal since 2015, it fosters transparency and accessibility in sharing critical knowledge pertaining to the diagnosis, assessment, and monitoring of Alzheimer’s disease and related dementias. With an impressive impact factor reflected in its Q1 rankings in both Neurology (Clinical) and Psychiatry and Mental Health, this journal is recognized for its significant contribution to advancing understanding and improving clinical practices, as evidenced by its Scopus rankings in the top percentiles. Researchers, healthcare professionals, and students are encouraged to engage with the latest findings and methodologies that shape the future of dementia care, enhancing both patient outcomes and the scientific community's response to this pressing health challenge. With its headquarters located in Hoboken, NJ, this journal is a pivotal platform for disseminating high-quality, peer-reviewed research that strives to combat one of the most challenging areas in medicine today.

Alzheimers & Dementia is a premier journal published by WILEY that focuses on the latest advancements in understanding, diagnosing, and treating Alzheimer's disease and other dementias. With an ISSN of 1552-5260 and an E-ISSN of 1552-5279, this influential journal boasts a commendable impact factor and ranks in the Q1 category across several disciplines, including *Cellular and Molecular Neuroscience*, *Geriatrics and Gerontology*, and *Neurology (Clinical)*. By publishing cutting-edge research, systematic reviews, and innovative clinical trials, Alzheimers & Dementia aims to bridge the gap between basic neuroscience and clinical practice, offering valuable insights into the etiology, epidemiology, and management of dementia-related disorders. The journal is hosted in the United States and operates under a balanced access model, providing essential resources for researchers, healthcare professionals, and students dedicated to tackling the challenges posed by these neurodegenerative diseases. Available online, it plays a pivotal role in shaping current and future research directions in the vibrant field of dementia studies.

The JOURNAL OF AGING AND HEALTH, published by SAGE PUBLICATIONS INC, is a preeminent peer-reviewed journal dedicated to advancing research in the field of gerontology and related disciplines. With an impressive impact factor and ranked Q1 across multiple categories including Community and Home Care, Geriatrics and Gerontology, and Health (Social Science), this journal has established itself as a vital resource for academics, clinicians, and policymakers alike. Spanning over three decades of publication from 1989 to 2024, it serves as a platform for innovative research and multifaceted discussions on aging, health, and the interplay of social factors influencing the elderly population. The journal's rigorous standards for publication ensure high-quality contributions that are impactful and relevant, making it an essential read for those dedicated to improving the health and quality of life for older adults. Although it is not an open-access journal, it provides comprehensive insights that are critical to understanding the complexities of aging in today's society.

npj Aging and Mechanisms of Disease is a leading open-access journal dedicated to advancing the understanding of the biological mechanisms underlying aging and age-related diseases. Published by NATURE PORTFOLIO in the United Kingdom, this journal has established itself as a vital resource within the fields of Aging and Geriatrics and Gerontology, proudly holding a prestigious Q1 ranking in both categories as of 2023. With an impressive Scopus ranking, placing it in the top 10 for Geriatrics and Gerontology, and the top 9 for Aging, the journal is committed to disseminating high-quality, peer-reviewed research that offers innovative insights and fosters collaboration among researchers and practitioners. Since its inception in 2015, npj Aging and Mechanisms of Disease has embraced the open-access model, ensuring that groundbreaking findings are freely available to all, thereby promoting widespread knowledge-sharing within the scientific community. This journal serves as an essential platform for those seeking to explore the complex interplay of genetic, molecular, and environmental factors that influence aging and its associated challenges.

The GERONTOLOGIST, published by Oxford University Press Inc, is a premier journal in the field of geriatrics and gerontology, with a distinguished history since its inception in 1961. This esteemed journal stands out with its impressive Q1 rankings in prominent categories, including Geriatrics and Gerontology, reflecting its vital role in disseminating innovative research and advancing knowledge within these critical disciplines. With an impact factor that ranks it among the top journals in both Nursing Gerontology and Medicine, the GERONTOLOGIST serves as a key resource for researchers, professionals, and students dedicated to enhancing the health and well-being of older adults. Although it operates under a traditional access model, the journal remains committed to publishing cutting-edge studies that address the complexities of aging and inform evidence-based practices. By fostering a rich dialogue among scholars and practitioners, the GERONTOLOGIST is instrumental in shaping the future of gerontological research and policy.

Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

Psychogeriatrics is a leading peer-reviewed journal published by WILEY, dedicated to advancing the understanding of mental health and geriatric psychiatry. With an ISSN of 1346-3500 and an E-ISSN of 1479-8301, this journal has been integral to the field since its inception in 2005 and continues to publish cutting-edge research until 2024. Recognized for its impact, Psychogeriatrics holds a commendable Q2 quartile ranking in Geriatrics and Gerontology, Gerontology, and Psychiatry and Mental Health as of 2023. The journal's Scopus rankings reflect its significant contribution to Nursing Gerontology, Medicine Psychiatry and Mental Health, and Medicine Geriatrics and Gerontology. Although it operates with no open access options, Psychogeriatrics remains a vital resource for researchers, professionals, and students who are exploring the complexities of mental health in older populations. The journal not only disseminates innovative research but also tackles pressing issues related to the psychological well-being of the elderly, making it essential reading for anyone focused on improving geriatric mental health care.

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.